Short answer
Rezolute, Inc. (RZLT) filed an 8-K current report with the SEC on September 24, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). FY2026 and fourth-quarter financial results announced for period ended June 30, 2026.
Rezolute, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- FY2026 and fourth-quarter financial results announced for period ended June 30, 2026
- Detailed results contained in Exhibit 99.1, the attached earnings press release
- Disclosure furnished under Item 2.02, limiting Exchange Act Section 18 liability and automatic incorporation by reference
Item EX-99.1 · Exhibit EX-99.1
- Fiscal 2026 net loss widened to $77.6M from $74.4M despite R&D falling to $53.8M
- Cash, equivalents and marketable securities declined to $107.8M from $167.9M, increasing future financing risk
- UpLIFT tumor HI enrollment continues, with topline results expected before year-end 2026
- Seven of eight enrolled participants met the primary responder criterion; one hospice-transition patient counted non-responder
- sunRIZE congenital HI results remain under FDA review after missing the primary endpoint, creating significant regulatory uncertainty
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Rezolute, Inc. 8-K filings
Get the next RZLT 8-K as it lands
Follow RZLT for push alerts, or ask the research agent what this filing means.